Moreover, in coronary artery disease (CAD) patients, CD31+/Annexin V+ EC-EVs have been associated with a worse clinical outcome, including an increased incidence of adverse cardiovascular and cerebral events [193]. This evidence concerns the gene ANXA5 and coronary artery disorder.